Showing 6411-6420 of 8687 results for "".
- Leading Melanoma Groups Unveil New Campaign Aimed at Menhttps://practicaldermatology.com/news/20120515-leading_melanoma_groups_unveil_new_campaign_aimed_at_men/2459800/
- Ulthera Cleared in Mexicohttps://practicaldermatology.com/news/20120320-ulthera_cleared_in_mexico/2459837/Ulthera is now registered in Mexico to market and distribute its ultrasound therapy device, the Ulthera System. In Mexico, the system is now prescribed to produce stimulation in tissues to raise the temperature in a localized manner for aesthetic
- Health Canada Approves BMS' Yervoy forhttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for/2459870/
- IFPA Highlights Patient Voices in Global Health Policy at UN Panelhttps://practicaldermatology.com/news/ifpa-highlights-patient-voices-in-global-health-policy/2483540/The International Federation of Psoriatic Disease Associations (IFPA) issued a call to global policymakers to recognize psoriatic disease as a serious noncommunicable disease (NCD) with system-wide implications at the 80th UN General Assembly in New York.
- From EADV: Rezpegaldesleukin Effective Through 24 Weeks in REZOLVE-AD Trialhttps://practicaldermatology.com/news/from-eadv-rezpegaldesleukin-effective-through-24-weeks-in-rezolve-ad-trial/2483465/New data from the REZOLVE-AD presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress demonstrated that investigational IL-2 pathway agonist rezpegaldesleukin sustained effect beyond the 16-week induction period in patients with moderat
- From EADV: Povorcitinib Maintains Efficacy Through 24 Weeks in STOP-HS Programhttps://practicaldermatology.com/news/from-eadv-povorcitinib-maintains-efficacy-through-24-weeks-in-hs-phase-3-data/2483429/New 24-week results from the phase 3 STOP-HS trial program suggest that investigational oral JAK1 inhibitor povorcitinib provided sustained clinical benefits in adults with moderate to severe hidradenitis suppurativa (HS), according to findings presented at the 2025
- From EADV: Bimekizumab Shows Sustained Efficacy in Plaque Psoriasis and HShttps://practicaldermatology.com/news/from-eadv-bimekizumab-shows-sustained-efficacy-in-plaque-psoriasis-and-hs/2483464/New data presented by UCB at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris showed sustained efficacy and tolerability for BIMZELX® (bimekizumab-bkzx) in both moderate-to-severe hidradenitis suppurativa (HS) and plaque psoriasis. <
- Psoriatic Disease Tied to Elevated APS Incidence: Studyhttps://practicaldermatology.com/news/psoriatic-disease-tied-to-elevated-aps-incidence-study/2483386/Data from a new cohort study has identified an increased risk of antiphospholipid syndrome (APS) in patients with psoriasis, particularly those with psoriatic arthritis (PsA). Researchers for the study matched 288,678 patients fro
- Galderma to Present Long-Term Nemluvio Data, Global Sensitive Skin Survey at EADV 2025https://practicaldermatology.com/news/galderma-to-present-long-term-nemluvio-data-global-sensitive-skin-survey-at-eadv-2025/2483331/Galderma will present new findings on sensitive skin, as well as long-term data on nemolizumab (Nemluvio®) at the 34th European Academy of Dermatology and Venereology (EADV) Congress, to be held in Paris, September 17–20, 2025, a press statement from the manufactur
- Incyte to Present STOP-HS, TRuE-PN Trials at EADV 2025https://practicaldermatology.com/news/late-breaking-hs-and-pn-data-to-anchor-incytes-eadv-presentations/2483330/Incyte announced that it will present new data from studies throughouts its dermatology pipeline at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, according to a press release from the manufacturer.